Equities analysts expect that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will post earnings per share (EPS) of ($0.91) for the current quarter, according to Zacks. Eight analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from ($2.20) to $0.91. Ultragenyx Pharmaceutical posted earnings per share of ($1.63) in the same quarter last year, which would suggest a positive year-over-year growth rate of 44.2%. The firm is scheduled to issue its next earnings results on Thursday, May 3rd.
On average, analysts expect that Ultragenyx Pharmaceutical will report full-year earnings of ($6.25) per share for the current financial year, with EPS estimates ranging from ($8.73) to ($2.54). For the next year, analysts expect that the business will post earnings of ($6.61) per share, with EPS estimates ranging from ($8.41) to ($5.20). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported ($2.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.00) by ($0.27). The company had revenue of $2.41 million for the quarter, compared to analyst estimates of $0.75 million. During the same period in the prior year, the company posted ($1.75) earnings per share.
A number of hedge funds have recently made changes to their positions in RARE. Ladenburg Thalmann Financial Services Inc. boosted its stake in Ultragenyx Pharmaceutical by 1,246.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,273 shares of the biopharmaceutical company’s stock valued at $152,000 after acquiring an additional 3,030 shares during the last quarter. SG Americas Securities LLC bought a new position in Ultragenyx Pharmaceutical in the third quarter valued at approximately $156,000. Xact Kapitalforvaltning AB bought a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $205,000. B. Riley Financial Inc. bought a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $213,000. Finally, Aperio Group LLC bought a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $254,000. 87.19% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded up $0.51 during trading on Friday, hitting $54.31. 60,219 shares of the company were exchanged, compared to its average volume of 606,654. The firm has a market capitalization of $2,668.79, a price-to-earnings ratio of -7.57 and a beta of 1.93. Ultragenyx Pharmaceutical has a fifty-two week low of $41.67 and a fifty-two week high of $88.95.
COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Ultragenyx Pharmaceutical Inc (RARE) to Announce -$0.91 Earnings Per Share” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/03/12/brokerages-expect-ultragenyx-pharmaceutical-inc-rare-to-announce-0-91-earnings-per-share.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.